Sponsored By:

We were unable to forward you to the advertisement you clicked on.

The likely cause for this is that your browser, feed reader, or email application is configured to not accept cookies, or your reader may launch an external browser to view links without sharing cookies.

  • If you're using Internet Explorer, make sure your privacy setting is at medium or below.
    • Select 'Internet Options' from the 'Tools' menu in your browser window
    • Click the Privacy tab
    • Adjust your privacy setting if necessary
      ?
  • If you're using a reader that embeds Internet Explorer (examples: Microsoft Outlook, Outlook Express, Feed Demon), you'll also need to select Internet Explorer as your default web browser.
    • Open Internet Explorer
    • Select 'Internet Options' from the 'Tools' menu in your browser window
    • Click the 'Programs' tab and check the box for Internet Explorer to check if it is the default browser and save your change
    • Close your browser, re-open it, and when prompted, select Internet Explorer as your default
    • You can then click on an ad in your newsletter and visit the site you wish to view

encyclopedia britannica pi white lion mike d antoni resigns holes ncaa brackets 2012 odd

Kim Kardashian and Kanye West: Totally in Love!!!


PR stunt, schmeer R stunt: Kanye West is totes in love with Kim Kardashian, according to Us Weekly sources.

"They're perfect for each other. He thinks she's his Beyonce," an insider says of Kanye's feelings, adding that the rapper has fallen "genuinely head over heels" for the reality star.

Kim Kardashian and Kanye West in Love!

Kim and Kanye have been friends since 2004, with this source claiming the latter pursued the former for a very long time.

Why did Kardashian finally give in to the relationship? We'll have to ask her mom and/or public relations team. Kim herself in mum on the topic of a romance with Kanye, while Kris Humphries doesn't care at all about the exploits of his ex.

scotty mccreery country music awards 2012 wrestlemania 28 results earl scruggs game of thrones game of thrones season 2 wrestlemania 28

David H. Koch donates $10 million to Mount Sinai's Jaffe Food Allergy Institute

[ Back to EurekAlert! ] Public release date: 10-Apr-2012
[ | E-mail | Share Share ]

Contact: Jeanne Bernard
Jeanne.Bernard@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

David H. Koch, Executive Vice President of Koch Industries, has committed $10 million to the Jaffe Food Allergy Institute at The Mount Sinai Medical Center. The gift is one of the largest in the Institute's history and will create the David H. and Julia Koch Research Program in Food Allergy Therapeutics. The program will serve as a hub for drug discovery and vaccine development related to food allergy, and build upon the promising work already underway at the Institute. The donation will also be used to further the Institute's recruitment of leading researchers dedicated to the discovery of new food allergy therapeutics.

Nearly 15 million Americans have food allergies, including approximately 6 million children, according the The Food Allergy & Anaphylaxis Network. A 2010 study led by Scott Sicherer, MD, Chief of the Division on Allergy and Immunology in the Department of Pediatrics and a clinical researcher at the Jaffe Food Allergy Institute found the rates of childhood peanut allergies, one of the most common and most dangerous food allergies, more than tripled between 1997 and 2008.

Because the preventive shots used for allergies such as pollen or bee stings cause severe unwanted side effects when used for food allergies, scientists at the Institute are conducting cutting-edge research investigating using small fragments of the three main allergenic proteins present in peanuts to create a "safe shot." If successful in preventing peanut allergy, the theory could be applied to vaccines for all food allergies. Mr. Koch's donation will support these studies as well as efforts to identify new targets and biomarkers for food allergy.

"This generous gift will strengthen Mount Sinai's position as a global leader in food allergy therapeutics," said Hugh Sampson, MD, Director of the Jaffe Food Allergy Institute and an internationally recognized allergist and investigator of food allergy. "Right now, the only recourse for patients who have food allergies is to avoid those foods. This program has the potential to deliver the first therapies and cures for food allergies."

The research conducted by the program will be especially significant for children's health, according to Kenneth L. Davis, President and CEO of The Mount Sinai Medical Center. "Breakthrough therapeutics such as these will change the face of children's health," he said. "Mr. Koch's visionary philanthropy brings us one step closer to that goal."

Mr. Koch is a major advocate for medical research, and has long supported research into food allergies. "This is an exhilarating time for science and medicine in food allergy, and Dr. Sampson and his team are the best at what they do, but the most exciting discoveries are yet to come," said Mr. Koch. "My hope is that in the not-too-distant future, children who suffer from life-threatening food allergies will have their lives transformed from the therapies that originated here."

The Jaffe Food Allergy Institute was established in 1997 with the mission to expand and improve basic science and clinical research, comprehensive patient care, and educational efforts in the field of food allergy. Recent findings and ongoing studies include:

  • The group recently published a study showing that introducing food products containing baked milk into the diets of children who have milk allergy helps the majority of them outgrow their milk allergy more quickly;
  • In the first-ever study to assess the social impact of food allergies in children, researchers led by Dr. Scott Sicherer, found that approximately 35 percent of children over the age of five with food allergies, experience bullying, teasing, or harassment as a result of their allergies;
  • A team led by Dr. Sampson is currently conducting a clinical trial investigating the effectiveness of oral immunotherapy combined with the anti-IgE medication omalizumab in the treatment of cow's milk allergy;
  • A team of investigators led by Julie Wang, MD, Assistant Professor of Allergy and Immunology and Xiu-Min Li, MD, Professor of Pediatrics, is currently conducting a clinical trial investigating the effectiveness of Chinese herbs as a treatment for peanut, tree nuts, sesame, fish, or shellfish allergies;
  • A team led by Dr. Sampson is investigating other novel forms of immunotherapy including peptide-based vaccines and engineered recombinant protein-based vaccines.

By combining a world-class clinical research program with an equally strong laboratory-based one, the Jaffe Food Allergy Institute is uniquely able to move ideas and investigations between the laboratory bench and the patient's bedside in order to approach these disorders as efficiently and creatively as possible. The major goal is to devise more definitive, hopefully curative, therapies for food allergic disease.

###

To find out more about the work being done at the Jaffe Food Allergy Institute visit: http://www.mssm.edu/research/programs/jaffe-food-allergy-institute.>

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2011, U.S. News & World Report ranked The Mount Sinai Hospital 16th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Of the top 20 hospitals in the United States, Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and US News & World Report and whose hospital is on the US News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

For more information, visit http://www.mountsinai.org/.

Find Mount Sinai on:
Facebook: http://www.facebook.com/mountsinainyc
Twitter: @mountsinainyc
YouTube: http://www.youtube.com/mountsinainy


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


[ Back to EurekAlert! ] Public release date: 10-Apr-2012
[ | E-mail | Share Share ]

Contact: Jeanne Bernard
Jeanne.Bernard@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

David H. Koch, Executive Vice President of Koch Industries, has committed $10 million to the Jaffe Food Allergy Institute at The Mount Sinai Medical Center. The gift is one of the largest in the Institute's history and will create the David H. and Julia Koch Research Program in Food Allergy Therapeutics. The program will serve as a hub for drug discovery and vaccine development related to food allergy, and build upon the promising work already underway at the Institute. The donation will also be used to further the Institute's recruitment of leading researchers dedicated to the discovery of new food allergy therapeutics.

Nearly 15 million Americans have food allergies, including approximately 6 million children, according the The Food Allergy & Anaphylaxis Network. A 2010 study led by Scott Sicherer, MD, Chief of the Division on Allergy and Immunology in the Department of Pediatrics and a clinical researcher at the Jaffe Food Allergy Institute found the rates of childhood peanut allergies, one of the most common and most dangerous food allergies, more than tripled between 1997 and 2008.

Because the preventive shots used for allergies such as pollen or bee stings cause severe unwanted side effects when used for food allergies, scientists at the Institute are conducting cutting-edge research investigating using small fragments of the three main allergenic proteins present in peanuts to create a "safe shot." If successful in preventing peanut allergy, the theory could be applied to vaccines for all food allergies. Mr. Koch's donation will support these studies as well as efforts to identify new targets and biomarkers for food allergy.

"This generous gift will strengthen Mount Sinai's position as a global leader in food allergy therapeutics," said Hugh Sampson, MD, Director of the Jaffe Food Allergy Institute and an internationally recognized allergist and investigator of food allergy. "Right now, the only recourse for patients who have food allergies is to avoid those foods. This program has the potential to deliver the first therapies and cures for food allergies."

The research conducted by the program will be especially significant for children's health, according to Kenneth L. Davis, President and CEO of The Mount Sinai Medical Center. "Breakthrough therapeutics such as these will change the face of children's health," he said. "Mr. Koch's visionary philanthropy brings us one step closer to that goal."

Mr. Koch is a major advocate for medical research, and has long supported research into food allergies. "This is an exhilarating time for science and medicine in food allergy, and Dr. Sampson and his team are the best at what they do, but the most exciting discoveries are yet to come," said Mr. Koch. "My hope is that in the not-too-distant future, children who suffer from life-threatening food allergies will have their lives transformed from the therapies that originated here."

The Jaffe Food Allergy Institute was established in 1997 with the mission to expand and improve basic science and clinical research, comprehensive patient care, and educational efforts in the field of food allergy. Recent findings and ongoing studies include:

  • The group recently published a study showing that introducing food products containing baked milk into the diets of children who have milk allergy helps the majority of them outgrow their milk allergy more quickly;
  • In the first-ever study to assess the social impact of food allergies in children, researchers led by Dr. Scott Sicherer, found that approximately 35 percent of children over the age of five with food allergies, experience bullying, teasing, or harassment as a result of their allergies;
  • A team led by Dr. Sampson is currently conducting a clinical trial investigating the effectiveness of oral immunotherapy combined with the anti-IgE medication omalizumab in the treatment of cow's milk allergy;
  • A team of investigators led by Julie Wang, MD, Assistant Professor of Allergy and Immunology and Xiu-Min Li, MD, Professor of Pediatrics, is currently conducting a clinical trial investigating the effectiveness of Chinese herbs as a treatment for peanut, tree nuts, sesame, fish, or shellfish allergies;
  • A team led by Dr. Sampson is investigating other novel forms of immunotherapy including peptide-based vaccines and engineered recombinant protein-based vaccines.

By combining a world-class clinical research program with an equally strong laboratory-based one, the Jaffe Food Allergy Institute is uniquely able to move ideas and investigations between the laboratory bench and the patient's bedside in order to approach these disorders as efficiently and creatively as possible. The major goal is to devise more definitive, hopefully curative, therapies for food allergic disease.

###

To find out more about the work being done at the Jaffe Food Allergy Institute visit: http://www.mssm.edu/research/programs/jaffe-food-allergy-institute.>

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2011, U.S. News & World Report ranked The Mount Sinai Hospital 16th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Of the top 20 hospitals in the United States, Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and US News & World Report and whose hospital is on the US News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

For more information, visit http://www.mountsinai.org/.

Find Mount Sinai on:
Facebook: http://www.facebook.com/mountsinainyc
Twitter: @mountsinainyc
YouTube: http://www.youtube.com/mountsinainy


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


toyota recall northern lights sign of the times keystone pipeline purim acc tournament big ten tournament

laptopmag: Prices Leaked for 7-inch and 10.1-inch Samsung Galaxy Tab 2 http://t.co/b2LYi4mQ

  • Passer la navigation
  • Twitter sur votre mobile ? Cliquez ici m.twitter.com!
  • Passer cette ?tape
  • Connexion
Loader Twitter.com
  • Connexion
Prices Leaked for 7-inch and 10.1-inch Samsung Galaxy Tab 2 bit.ly/Ij716U laptopmag

LAPTOP Magazine

Pied de page

tim tebow press conference tebow press conference trina andy roddick rob dyrdek oberon donald driver

Itraconazole in treatment of mCRPC: an update - New Prostate ...

Researchers at Johns Hopkins have, for a while, been investigating the potential of the antifungal agent itraconazole as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). We last reported on this research nearly a year ago, based on a presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2011.

Anonarakis and his colleagues have now provided final results from the randomized Phase II trial of two different doses of itraconazole (either 200 or 600 mg/day). Their data were presented last week at the annual meeting of the American Association for Cancer Research (AACR) in Chicago.

According to the published abstract and a report on the MedPageToday web site:

  • 46 men with mCRPC were randomized to be treated with one of two doses of itraconazole.
    • 17 men received itraconazole at a dosage of 200 mg/day but enrolled ment of patients at this dosage was stopped ?for futility? (i.e., because it was insufficiently effective).
    • 29 men received itraconazole at a dosage of 600 mg/day.
  • Patients were followed until clinical or radiographic progression was observed or until development of unacceptable toxicity.
  • The primary study endpoint was the proportion of patients with PSA-based progression-free survival (PPFS) at 24 weeks (defined as a ?25 percent increase in PSA level from baseline or nadir PSA, based on two PSA measurements taken 4 weeks apart).
  • Secondary endpoints included
    • Progression-free survival (PFS) at 24 weeks (based on clinical/radiographic progression or death, but not rising PSA)
    • Median PFS
    • Median PPFS
    • Maximum decline in PSA levels
  • Progression was defined as a ?25 percent increase in PSA level and a 2 ng/mL rise from baseline or nadir PSA, based on two PSA measurements taken 4 weeks apart.

The study results reported by Antonarakis et al. are as follows:

  • The average (median) age of the patients was about 72 years.
  • Patients had an average of 6.5 metastases, and had previously received an average of 2.5 hormonal therapies.
  • About 33 percent of patients in each arm had a history of treatment with ketaconazole.
  • The average (median) follow-up on treatment with itraconazole was 11.9 weeks in the low-dose arm and 21.6 weeks in the high-dose arm.
  • For men in the high-dose itraconazole group
    • 4/29 patients (14 percent) had PSA decreases of > 50 percent.
    • Another 4/29 patients (14 percent) had PSA decreases of ? 30 percent.
    • 14/29 patients (48 percent) demonstrated PPFS at 24 weeks.
    • 17/29 patients (62 percent) demonstrated PFS at 24 weeks.
    • Median PPFS was 17 weeks.
    • Median PFS was 36 weeks.
  • For men in the low-dose itraconazole group
    • No patients had PSA decreases of > 50 percent.
    • 2/17 patients (12 percent) demonstrated PPFS at 24 weeks.
    • 3/16 patients (19 percent) demonstrated PFS at 24 weeks.
    • Median PPFS was 11.9 weeks.
    • Median PFS was 11.9 weeks.

Antonarakis and his colleagues have suggested that itraconazole at a dose of 600 mg/d could potentially be used to delay disease progression in men with mCRPC and no prior exposure to chemotherapy. They also have noted that itraconazole does not suppress adrenal androgens (as compared with the similar antifungal agent ketoconazole).

The apparent clinical effects of itraconazole may not, however, be sufficient on their own to have major utility with the availability of drugs like abiraterone acetate and (potentially) enzalutimide (MDV3100). However, one is tempted to wonder whether combinations of abiraterone + itraconazole or enzalutimide + itraconazole might have significant impact in the management of men with chemotherapy-naive mCRPC.

Itraconazole is an oral, generically available, low-cost, antifungal agent. It therefore has the potential to be used easily and relatively cheaply in combination with drugs like abiraterone and enzalutimide. However, whether it is safe and effective to use in such combinations will need further exploratory trials. Data available to date suggest that itraconazole can be given with relative safety to men with mCRPC. However, itraconazole is not a benign drug. It has a well-understood history of side effects that can include fatigue, nausea, anorexia, rash, hypokalemia, hypertension, edema, and even heart failure in some patients.

Like this:

Be the first to like this post.

seal and heidi klum drew peterson untouchable herman cain south carolina denver nuggets palmetto rob lowe fox news

Casino Game 42 ? Blog Archive ? Online Casino News

Casino news is an important source for information in many different ways. You can learn more about an online casino that you are interested in simply by following the latest news about it. It can also be an eye opener and show you where the coolest gaming action can be found. Last but not least, online casino news is a great source of inspiration and a way for you to learn about other players winning in the casino where you can also take part in the action.

Learn more about gaming online

When a player starts to play regularly in casinos online it can be very useful to follow casino news. The specific online casino will send out its own news in a newsletter and this is something that you don?t want to miss. If you are not getting the newsletter it could be because your email program sends it automatically to your spam filter. Check the spam folder and label the newsletter as regular mail so that you won?t miss out on the latest offers in your casino.

Find the best deals

By reading the newsletters you find out about the best deal in the casino where you are already a member, but to learn about other casinos you need to check news in regular gaming forums online. Here you will see that the same game that you saw as a new introduction in your regular casino is also introduced in other casinos but with a great bonus. This can influence how you choose to play and how much you get for your deposits and bets.

Get inspiration for your gaming

The inspiration that one can get from online casino news is very important. There are always stories about players winning big at online casinos. It could be that someone won a poker tournament without being a poker star to begin with or that someone hit the millions with one spin on a slot machine. It tells you that the same thing can happen to you!

ryan leaf anchorman 2 kentucky basketball oaksterdam the fray national anthem dallas tornado morris claiborne

Animal Lover Leona Lewis Hits Hopefield's Easter Fair

Posted Sunday April 8, 2012 7:26 PM GMT

Spending the day with furry friends, Leona Lewis was spotted at the Hopefield Animal Sanctuary Easter Fair in Brentwood, England on Sunday (April 8).

The "Keep Bleeding" singer - who's a trustee and patron for the agency which takes in abused and neglected animals - cuddled with a pooch under her warm coat as she walked to visit the outdoor animals in rain boots.

During the event, Miss Lewis posted a picture of two pigs laying side by side while adding a caption reading, "Rescue piglets at hopefield awwww"

In a statement for the organization, the 27-year-old gushed about how thankful she is for the sanctuary, saying in part, "My mission at Hopefield is to make sure these animals can continue to live here, that they can live comfortably and safely, that we can build Hopefield into a sanctuary that will educate people on animal welfare and continue to save more animals in need."

Enjoy the photos of Leona Lewis at the Hopefield Animal Sanctuary Easter Fair in Brentwood, England (April 8).

Article Pictures (Click To Enlarge):-->

the thin man republic wireless space ball drops on namibia matt barkley melanie amaro x factor boise state jordans

SPE? TPO Auto. Engineered Polyolefins Conference Announces ...

The fourteenth-annual SPE? TPO Automotive Engineered Polyolefins Conference, the world?s leading automotive engineered-polyolefins forum, which is organized by the Detroit Section of the Society of Plastics Engineers (SPE?) and this year runs from September 30-October 3, 2012, will feature five keynote speakers who will highlight important trends that are reshaping the global automotive-plastics market. According to Bill Windscheif, conference chair and president, Advanced Innovative Solutions, ?The 2008-2009 global automotive crash triggered major changes in the engineered polyolefins supply chain that are still impacting the industry three-and-a-half years later. That?s why our committee intersperses keynote talks throughout the conference to help attendees better understand challenges and opportunities still facing the automotive-supply community.?

The conference will open on Monday morning with a keynote by Exxon Mobil Corp. Energy Advisor Vincent Yuskiewicz who will give a talk entitled The Outlook for Energy: A View to 2040, which will address a long-term view of the world?s energy future, including the more efficient use of energy through technologies such as hybrid vehicles.

Yuskiewicz will discuss global energy demand, which is expected to rise by about 30 percent from 2010 to 2040. ?ExxonMobil expects that demand growth would be approximately four times that amount without projected gains in efficiency,? he says. ?Efficiency is the key reason why energy demand will rise by only about 1 percent a year on average even as global GDP rises by nearly 3 percent a year. It also is the reason why energy demand in the developed world will remain relatively unchanged through 2040 even as its economic output nearly doubles. In transportation, ExxonMobil sees advanced vehicles, including hybrids, accounting for 50 percent of the cars people will drive in 2040, compared to about 1 percent today. This, plus improved fuel economy in conventional vehicles, will cause demand for energy for personal vehicles to remain essentially flat through 2040 even as the number of personal vehicles in the world doubles.?

After lunch on Monday, Patrick (Pat) Stewart, vice-president and executive director of Interior Systems at Inteva Products, LLC will speak on the topic of Innovative Concepts for Automotive Interiors.

About his topic, Stewart says, ?The automotive interior continues to evolve into a home away from home. What the OEMs considered luxury 5 years ago is now being styled into entry-level and mid-level vehicles. In addition, the pressure on fuel economy continues to drive the need for lower mass materials and systems. The challenge for the supplier is to deliver innovative materials and solutions to enable the styling, manage total system cost to the price point of the vehicle, with no sacrifice in performance, durability, and safety.?

On Tuesday morning, Mary-Beth Kellenberger, director-Global Automotive Aftermarket Research, Frost & Sullivan, will speak on Throwing Light On the Future: Mega Trends and their Ability to Shape Personal Mobility.

Kellenberger explains, ?This presentation will examine a variety of mega trends currently at work in society at large and discuss how they will impact personal mobility and the vehicles we use for personal mobility. We?ll cover topics like the evolution of urbanization and smart cities, including implicit social changes, business-model evolution, and a look at the countries in 2020 that will be the next game changers beyond the BRIC (Brazil, Russia, India, China) nations. We?ll also review the evolution of personal commuting and its effects on personal vehicles, and then explore future mobility innovations, including multi-modal commuting and alternative transportation plans already underway at various automakers. Since smart is the new green, we?ll define what a smart connected car is and what that implies. We?ll also look at the top 50 emerging vehicle technology trends, take a snapshot of a ?Zero-Concept? world in 2020, and then conclude with how to view from the macro level but implement from the micro level.?

Tuesday afternoon will feature a keynote on Global Polyolefins Overview by Howard Rappaport, senior director-Global Plastics at IHS Chemical at this year?s conference.

Rappaport notes, ?The global polyolefin market is changing dramatically in response to the fast-advancing industrialization process in emerging markets, as well as improvements in global communications and trade liberalization. Investments are increasingly concentrated in feedstock cost-advantaged or high-demand growth areas, like the Middle East and the Asia/Pacific region. The same trend, particularly in West Europe, is driving industry consolidation, operations optimization, and moves toward the production of higher value, performance products. In North America, low-cost feedstock from shale gas is revitalizing the polyethylene (PE) business, making PE exports highly competitive globally. Growth in polyolefin consumption will be mainly driven by the rapid economic development of numerous transition countries in the Asia/Pacific region, Central Europe, the Middle East, and South America. Higher monomer prices have significantly reduced the cost advantage polypropylene previously enjoyed vs. other polymers and that is limiting growth prospects in lower-end packaging applications. Recent high volatility in polypropylene prices and tight feedstock supplies, particularly in North America, are also adversely affecting consumption. Yet, polypropylene?s excellent properties and versatility will continue to open new and higher value markets. The future shows continued strong consumption growth.?

And Wednesday will start off with a keynote from Alexander (Alex) Buechler, owner and publisher of HB Media who will give a talk about about Less Polypropylene in Automotive Applications.

?An average passenger car contains 130 pounds (60 kilograms) of polypropylene,? says Buechler, ?but each year that number drops by approximately 0.70 pounds (0.33 kilograms) due to better flowing materials, which allow wall stock to be reduced; use of foamed polypropylene that lowers mass; and reduction in heavy fillers like talc ? all of which means less polypropylene in our cars. We will show which components are most affected, as well as the vehicle segments where polypropylene is making a particularly strong return. Contradictory trends in North America, Europe, and Asia are also covered.?

Since 1998, the SPE TPO Automotive Engineered Polyolefins Conference has highlighted the importance of rigid and flexible polyolefins throughout the automobile ? in applications ranging from semi-structural composite underbody shields and front-end modules to soft-touch interior skins and bumper fascia. Engineered polyolefins have been the fastest-growing segment of the global plastics industry for more than a decade owing to their excellent cost/performance ratio. The show typically draws approximately 500 attendees from 20 countries on four continents who are interested in learning about the latest in rigid and elastomeric TPO as well as TPE and TPV technologies. Fully a third of conference attendees say they work for a transportation OEM, and roughly 20% work for a tier integrator/molder, with the balance from materials or reinforcement suppliers, equipment OEMs, industry consultants, and members of academia. This year?s conference returns to the Troy Marriott in the Detroit suburbs. A variety of sponsorship packages are available for companies interested in showcasing their products and/or services.

The mission of SPE International is to promote scientific and engineering knowledge relating to plastics worldwide and to educate industry, academia, and the public about these advances. SPE?s Detroit Section is active in educating, promoting, recognizing, and communicating technical accomplishments for all phases of plastics and plastic based-composite developments ? particularly in the automotive industry. Topic areas include applications, materials, processing, equipment, tooling, design, and development.

For more information about the SPE TPO Automotive Engineered Polyolefins Conference, to view the conference?s evolving technical program, or to register to attend the event, please visit http://auto-tpo.com/ or http://speautomotive.com/tpo.htm, or call the group at +1.248.244.8993, or write SPE Detroit Section, 1800 Crooks Road, Suite A, Troy, MI 48084, USA. For more information on the Society of Plastics Engineers or other SPE events, visit the SPE website at www.4spe.org, or call +1.203.775.0471.

# # # # #

? SPE is a registered trademark of the Society of Plastics Engineers. All other trademarks are the property of their respective owners.

Like this:

Be the first to like this post.

grand theft auto 5 kris jenner kris jenner livestand kelly slater kelly slater palindrome

Infrastructure Finance: Trends and Techniques | Cheap Airline Tickets

Infrastructure Finance: Trends and Techniques

Product Description

Infrastructure Finance gives a broad view of trends and techniques in global infrastructure financing today. The many specialist contributors to the book discuss the infrastructure needs in their specific regions including Latin America, the Carribean, Africa, Middle East, South Asia - and considers a wide range of projects including transport, water systems, healthcare, power and toll road privatisation. Themes include the rising need for infrastructure investment, the quality of country infrastructure, different types of financing (including Shariah-compliant financing), government budget limitations, credit ratings, accounting, and benefits and risks of investment. Includes case studies of past projects. The following topics are discussed in detail, infrastructure needs worldwide, Public Private Partnerships, government accounting issues, infrastructure financing techniques, sources of infrastructure financing, financing health care facilities, airport financing, credit rating of infrastructure projects. Edited by Henry A. Davis with contributions from 57 specialist contributors, which include: bankers, lawyers, consultants, economists, academics, project developers, insurance underwriters, investment analysts, credit rating analysts, government officials, and multilateral agency officials.

Details

No features available.

Manufactured by Euromoney Institutional Investor

View All Customer Reviews

Tell A Friend

Infrastructure Finance: Trends and Techniques out of 5 based on ratings. 0 user reviews

Products Infrastructure Finance: Trends and Techniques Infrastructure Finance gives a broad view of trends and techniques in global infrastructure financing today. The many specialist contributors to the book discuss the infrastructure needs in their specific regions including Latin America, the Carribean, Africa, Middle East, South Asia - and considers a wide range of projects including transport, water systems, healthcare, power and toll road privatisation. Themes include the rising need for infrastructure investment, the quality of country infrastructure, different types of financing (including Shariah-compliant financing), government budget limitations, credit ratings, accounting, and benefits and risks of investment. Includes case studies of past projects. The following topics are discussed in detail, infrastructure needs worldwide, Public Private Partnerships, government accounting issues, infrastructure financing techniques, sources of infrastructure financing, financing health care facilities, airport financing, credit rating of infrastructure projects. Edited by Henry A. Davis with contributions from 57 specialist contributors, which include: bankers, lawyers, consultants, economists, academics, project developers, insurance underwriters, investment analysts, credit rating analysts, government officials, and multilateral agency officials. $327.00

Media_httpecximagesam_meewl

http://www.blueohioblog.com/2012/04/infrastructure-finance-trends-and-techniq...

Technorati Tags: Finance:, Infrastructure, Techniques, Trends

nsx chad ochocinco roman numerals new england patriots patriots nbc madonna